Nautilus Biotechnology (NAUT) Current Assets (2020 - 2026)

Nautilus Biotechnology has disclosed Current Assets across 7 years of filings, most recently posting $98.8 million for Q1 2026.

• Current Assets for Q1 2026 came in at $98.8 million, down 30.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $98.8 million (down 30.2% YoY), and the FY2025 annual result was $106.0 million, down 20.22% from the prior year.
• Current Assets came in at $98.8 million for Q1 2026 at Nautilus Biotechnology, down from $106.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $327.1 million in Q1 2022 to a low of $98.8 million in Q1 2026.
• The 5-year median for Current Assets is $170.5 million (2023), against an average of $179.1 million.
• Across the five-year window, Current Assets surged 34856.29% in 2022 and sank 47.87% in 2023, its largest moves.
• Nautilus Biotechnology's Current Assets stood at $187.2 million in 2022, then declined by 5.54% to $176.8 million in 2023, then slipped by 24.89% to $132.8 million in 2024, then dropped by 20.22% to $106.0 million in 2025, then slipped by 6.73% to $98.8 million in 2026.
• The last three Current Assets figures came in at $98.8 million (Q1 2026), $106.0 million (Q4 2025), and $134.3 million (Q3 2025), per Business Quant data.